Pages that link to "Q44872787"
Jump to navigation
Jump to search
The following pages link to Acenocoumarol stabilization is delayed in CYP2C93 carriers (Q44872787):
Displaying 25 items.
- Translating pharmacogenomics: challenges on the road to the clinic (Q21092371) (← links)
- Applications of CYP450 testing in the clinical setting (Q24621760) (← links)
- Pharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumon (Q27006860) (← links)
- Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol (Q28288315) (← links)
- Expectations, validity, and reality in pharmacogenetics (Q33926313) (← links)
- Coumarin anticoagulants and co-trimoxazole: avoid the combination rather than manage the interaction (Q35880928) (← links)
- The pharmacogenetics of coumarin therapy. (Q36192806) (← links)
- Pharmacogenetics of target genes across the warfarin pharmacological pathway (Q36656419) (← links)
- The clinical role of genetic polymorphisms in drug-metabolizing enzymes (Q36840621) (← links)
- Pharmacoeconomic evaluations of pharmacogenetic and genomic screening programmes: a systematic review on content and adherence to guidelines (Q37194753) (← links)
- Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin (Q37195550) (← links)
- Evidence for a pharmacogenetic adapted dose of oral anticoagulant in routine medical practice (Q37256499) (← links)
- Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans (Q37376879) (← links)
- Pharmacogenetics of cardiovascular drug therapy (Q37430401) (← links)
- Thromboprophylaxis in total hip-replacement surgery in Europe: acenocoumarol, fondaparinux, dabigatran and rivaroxban (Q40247438) (← links)
- P-glycoprotein: a clue to vitamin K antagonist stabilization (Q41535282) (← links)
- CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: a case-control study (Q42910083) (← links)
- Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design (Q43258272) (← links)
- Variability in CYP2C9 allele frequency: a pilot study of its predicted impact on warfarin response among healthy South and North Indians (Q43708731) (← links)
- Effects of CYP2C9 and VKORC1 on INR variations and dose requirements during initial phase of anticoagulant therapy (Q45880221) (← links)
- Impact of CYP2C9 polymorphisms on the vulnerability to pharmacokinetic drug-drug interactions during acenocoumarol treatment (Q46702584) (← links)
- Pharmacogenetics of acenocoumarol: CYP2C9, CYP2C19, CYP1A2, CYP3A4, CYP3A5 and ABCB1 gene polymorphisms and dose requirements (Q46894635) (← links)
- Influence of CYP2C9 and VKORC1 polymorphisms on warfarin and acenocoumarol in a sample of Lebanese people. (Q51739644) (← links)
- The genetic interaction between VKORC1 c1173t and calumenin a29809g modulates the anticoagulant response of acenocoumarol. (Q53233863) (← links)
- Warfarin pharmacogenetics (Q81887452) (← links)